477 related articles for article (PubMed ID: 26510188)
41. An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression.
Zhang P; Shi B; Gao H; Jiang H; Kong J; Yan J; Pan X; Li K; Zhang P; Yao M; Yang S; Gu J; Wang H; Li Z
Cancer Immunol Immunother; 2014 Feb; 63(2):121-32. PubMed ID: 24177984
[TBL] [Abstract][Full Text] [Related]
42. [T-cells activated with a trifunctional bi-specific antibody in head and neck cancer].
Gronau S; Schmitt M; Reinhardt P; Wiesneth M; Riechelmann H
Laryngorhinootologie; 2005 Nov; 84(11):822-8. PubMed ID: 16358189
[TBL] [Abstract][Full Text] [Related]
43. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.
Laszlo GS; Gudgeon CJ; Harrington KH; Walter RB
Blood Cancer J; 2015 Aug; 5(8):e340. PubMed ID: 26295610
[TBL] [Abstract][Full Text] [Related]
44. Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy.
Zimmerman Z; Maniar T; Nagorsen D
Int Immunol; 2015 Jan; 27(1):31-7. PubMed ID: 25239133
[TBL] [Abstract][Full Text] [Related]
45. A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells.
Yamamoto K; Trad A; Baumgart A; Hüske L; Lorenzen I; Chalaris A; Grötzinger J; Dechow T; Scheller J; Rose-John S
Biochem J; 2012 Jul; 445(1):135-44. PubMed ID: 22509934
[TBL] [Abstract][Full Text] [Related]
46. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
Weiner GJ; Hillstrom JR
J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
[TBL] [Abstract][Full Text] [Related]
47. Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing.
Ross SL; Sherman M; McElroy PL; Lofgren JA; Moody G; Baeuerle PA; Coxon A; Arvedson T
PLoS One; 2017; 12(8):e0183390. PubMed ID: 28837681
[TBL] [Abstract][Full Text] [Related]
48. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.
Hayden MS; Linsley PS; Gayle MA; Bajorath J; Brady WA; Norris NA; Fell HP; Ledbetter JA; Gilliland LK
Ther Immunol; 1994 Jan; 1(1):3-15. PubMed ID: 7584477
[TBL] [Abstract][Full Text] [Related]
49. Functional analysis of bispecific antibody (EpCAMxCD3)-mediated T-lymphocyte and cancer cell interaction by single-cell force spectroscopy.
Hoffmann SC; Wabnitz GH; Samstag Y; Moldenhauer G; Ludwig T
Int J Cancer; 2011 May; 128(9):2096-104. PubMed ID: 20635391
[TBL] [Abstract][Full Text] [Related]
50. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Brischwein K; Schlereth B; Guller B; Steiger C; Wolf A; Lutterbuese R; Offner S; Locher M; Urbig T; Raum T; Kleindienst P; Wimberger P; Kimmig R; Fichtner I; Kufer P; Hofmeister R; da Silva AJ; Baeuerle PA
Mol Immunol; 2006 Mar; 43(8):1129-43. PubMed ID: 16139892
[TBL] [Abstract][Full Text] [Related]
51. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
Ren-Heidenreich L; Davol PA; Kouttab NM; Elfenbein GJ; Lum LG
Cancer; 2004 Mar; 100(5):1095-103. PubMed ID: 14983507
[TBL] [Abstract][Full Text] [Related]
52. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
53. Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM.
Warnders FJ; Waaijer SJ; Pool M; Lub-de Hooge MN; Friedrich M; Terwisscha van Scheltinga AG; Deegen P; Stienen SK; Pieslor PC; Cheung HK; Kosterink JG; de Vries EG
J Nucl Med; 2016 May; 57(5):812-7. PubMed ID: 26848172
[TBL] [Abstract][Full Text] [Related]
54. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct.
Brandl C; Haas C; d'Argouges S; Fisch T; Kufer P; Brischwein K; Prang N; Bargou R; Suzich J; Baeuerle PA; Hofmeister R
Cancer Immunol Immunother; 2007 Oct; 56(10):1551-63. PubMed ID: 17310380
[TBL] [Abstract][Full Text] [Related]
55. Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response.
Sapski S; Beha N; Kontermann RE; Müller D
Cancer Immunol Immunother; 2020 Nov; 69(11):2291-2303. PubMed ID: 32504247
[TBL] [Abstract][Full Text] [Related]
56. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
[TBL] [Abstract][Full Text] [Related]
57. The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.
Harrington KH; Gudgeon CJ; Laszlo GS; Newhall KJ; Sinclair AM; Frankel SR; Kischel R; Chen G; Walter RB
PLoS One; 2015; 10(8):e0135945. PubMed ID: 26305211
[TBL] [Abstract][Full Text] [Related]
58. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.
Kufer P; Mack M; Gruber R; Lutterbüse R; Zettl F; Riethmüller G
Cancer Immunol Immunother; 1997; 45(3-4):193-7. PubMed ID: 9435872
[TBL] [Abstract][Full Text] [Related]
59. Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1
Hong R; Zhou Y; Tian X; Wang L; Wu X
Int Immunopharmacol; 2018 Jan; 54():118-124. PubMed ID: 29128855
[TBL] [Abstract][Full Text] [Related]
60. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.
Mau-Sørensen M; Dittrich C; Dienstmann R; Lassen U; Büchler W; Martinius H; Tabernero J
Cancer Chemother Pharmacol; 2015 May; 75(5):1065-73. PubMed ID: 25814216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]